Ataluren use in patients with nonsense mutation Duchenne muscular dystrophy: patient demographics and characteristics from the STRIDE Registry
Translarna, INN-ataluren
Ataluren (Translarna) drug for Duchenne Muscular Dystrophy | New Drug Approvals
Biomedicines | Free Full-Text | Novel Translational Read-through–Inducing Drugs as a Therapeutic Option for Shwachman-Diamond Syndrome
Ataluren---EMA批准的蛋白表达修复新药
PTC Receives Positive CHMP Opinion For Translarna In DMD
Ataluren - Wikipedia
Translarna (ataluren) for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) - Clinical Trials Arena
Ataluren | C15H9FN2O3 - PubChem
PTC Therapeutics Receives Positive Opinion from CHMP for Translarna ( Ataluren) – PPMD Community
Ataluren: An Investigational Dystrophin Restoration Drug for Nonsense Mutation Duchenne Muscular Dystrophy
Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet
CHMP Favors Translarna Label Update Include Non-ambulatory DMD
Translarna (ataluren) for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) - Clinical Trials Arena
Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy
Ataluren---EMA批准的蛋白表达修复新药
DMD Aileleri Derneği on Twitter: "PTC Therapeutics, non-sense (anlamsız) mutasyon sebebiyle oluşan Duchenne tedavisine yönelik Ataluren (Translarna) ilacının FDA onay sürecine dair bir duyuru yayınladı. Not: İlaç, 2014'te EMA onayı almıştır. 5
Frontiers | Off-Label Use of Ataluren in Four Non-ambulatory Patients With Duchenne Muscular Dystrophy: Effects on Cardiac and Pulmonary Function and Muscle Strength
CHMP summary of positive opinion for Translarna
Andy Biotech on Twitter: "EMA CHMP Jan Meeting Highlights http://t.co/0wgIFR8c6r Negative on $PTCT ataluren, $TEVA $ACTI.ST laquinimod, etc http://t.co/QvuSFipItp" / Twitter
PTC Therapeutics Announces CHMP Recommendation of Translarna™ (ataluren) Label Update for Non-Ambulatory Patients with Duchenn
PTC Therapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Ataluren in Duchenne Muscular Dystrophy
Translarna, INN-ataluren
Document
Translarna, INN- ataluren
NHS England Enables Access to Translarna™ ▽ (ataluren) For Patients with Nonsense Mutation Duchenne Muscular Dystrophy
